CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
11 02 2021
Historique:
received: 29 06 2020
accepted: 04 10 2020
pubmed: 6 11 2020
medline: 2 7 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

Acute graft-versus-host-Disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). We previously showed that early CD4+ T-cell immune reconstitution (IR; CD4+ IR) predicts survival after HCT. Here, we studied the relation between CD4+ IR and survival in patients developing aGVHD. Pediatric patients undergoing first allogeneic HCT at University Medical Center Utrecht (UMC)/Princess Máxima Center (PMC) or Memorial Sloan Kettering Cancer Center (MSK) were included. Primary outcomes were nonrelapse mortality (NRM) and overall survival (OS), stratified for aGVHD and CD4+ IR, defined as ≥50 CD4+ T cells per μL within 100 days after HCT or before aGVHD onset. Multivariate and time-to-event Cox proportional hazards models were applied, and 591 patients (UMC/PMC, n = 276; MSK, n = 315) were included. NRM in patients with grade 3 to 4 aGVHD with or without CD4+ IR within 100 days after HCT was 30% vs 80% (P = .02) at UMC/PMC and 5% vs 67% (P = .02) at MSK. This was associated with lower OS without CD4+ IR (UMC/PMC, 61% vs 20%; P = .04; MSK, 75% vs 33%; P = .12). Inadequate CD4+ IR before aGVHD onset was associated with significantly higher NRM (74% vs 12%; P < .001) and inferior OS (24% vs 78%; P < .001). In this retrospective analysis, we demonstrate that early CD4+ IR, a simple and robust marker predictive of outcomes after HCT, is associated with survival after moderate to severe aGVHD. This association must be confirmed prospectively but suggests strategies to improve T-cell recovery after HCT may influence survival in patients developing aGVHD.

Identifiants

pubmed: 33150379
pii: S0006-4971(21)00281-0
doi: 10.1182/blood.2020007905
pmc: PMC7986048
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

848-855

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2021 by The American Society of Hematology.

Références

Stem Cell Investig. 2017 May 16;4:38
pubmed: 28607912
Bone Marrow Transplant. 2015 Sep;50(9):1227-34
pubmed: 26052909
N Engl J Med. 2016 Jan 7;374(1):43-53
pubmed: 26735993
J Allergy Clin Immunol. 2017 Dec;140(6):1643-1650.e9
pubmed: 28392330
Clin Pharmacokinet. 2015 Apr;54(4):435-46
pubmed: 25466602
Sci Transl Med. 2013 Apr 3;5(179):179ra43
pubmed: 23552371
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Biol Blood Marrow Transplant. 2015 Nov;21(11):1955-62
pubmed: 26187864
N Engl J Med. 2011 Dec 1;365(22):2055-66
pubmed: 22129252
Biol Blood Marrow Transplant. 2013 Feb;19(2):305-13
pubmed: 23092812
Clin Pharmacokinet. 2019 May;58(5):627-637
pubmed: 30327943
Biol Blood Marrow Transplant. 2015 Mar;21(3):473-82
pubmed: 25485863
Biol Blood Marrow Transplant. 2010 Jul;16(7):915-26
pubmed: 20226870
Blood. 2011 Jan 20;117(3):1061-70
pubmed: 20952687
Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S54-9
pubmed: 18978746
Bone Marrow Transplant. 2014 Feb;49(2):168-73
pubmed: 23892326
Biol Blood Marrow Transplant. 2017 Apr;23(4):625-634
pubmed: 28104514
Bone Marrow Transplant. 2016 Oct;51(10):1376-1378
pubmed: 27159172
Acta Neurol Scand. 2009 Apr;119(4):239-45
pubmed: 18771523
Nat Med. 2003 Sep;9(9):1144-50
pubmed: 12925844
Biol Blood Marrow Transplant. 2010 Jul;16(7):907-14
pubmed: 20302964
Leuk Res. 2017 Jun;57:60-64
pubmed: 28292719
Haematologica. 2019 Jul;104(7):1309-1321
pubmed: 31221786
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Biol Blood Marrow Transplant. 2009 Jul;15(7):881-5
pubmed: 19539221
Blood. 2016 Dec 8;128(23):2734-2741
pubmed: 27702800
J Allergy Clin Immunol. 2016 Jan;137(1):306-309.e4
pubmed: 26194539
Lancet Haematol. 2017 Apr;4(4):e183-e191
pubmed: 28330607
Lancet Haematol. 2015 May;2(5):e194-203
pubmed: 26688094
Bone Marrow Transplant. 1989 Jan;4(1):107-12
pubmed: 2647173
Bone Marrow Transplant. 2016 May;51(5):668-74
pubmed: 26808573
Blood. 2017 Aug 3;130(5):677-685
pubmed: 28588018
Biol Blood Marrow Transplant. 2016 May;22(5):902-9
pubmed: 26860636
Blood. 2018 Jun 21;131(25):2846-2855
pubmed: 29545329
Biol Blood Marrow Transplant. 2015 Oct;21(10):1839-45
pubmed: 26119367
Cytotherapy. 2020 Sep;22(9):503-510
pubmed: 32622752
Clin Cancer Res. 2014 Apr 15;20(8):2215-25
pubmed: 24573552
JCI Insight. 2017 Feb 9;2(3):e89798
pubmed: 28194439
Blood. 2006 Aug 15;108(4):1291-7
pubmed: 16627754

Auteurs

Coco de Koning (C)

Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

Susan Prockop (S)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Ichelle van Roessel (I)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Nancy Kernan (N)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Elizabeth Klein (E)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Jurgen Langenhorst (J)

Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

Celina Szanto (C)

Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Mirjam Belderbos (M)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Marc Bierings (M)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Farid Boulad (F)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Dorine Bresters (D)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Maria Cancio (M)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Kevin Curran (K)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Wouter Kollen (W)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Richard O'Reilly (R)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Andromachi Scaradavou (A)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Barbara Spitzer (B)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.

Birgitta Versluijs (B)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Alwin Huitema (A)

Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; and.
Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Caroline Lindemans (C)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Stefan Nierkens (S)

Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Jaap Jan Boelens (JJ)

Pediatric Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH